These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37489574)

  • 21. Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
    Regensburger M; Ip CW; Kohl Z; Schrader C; Urban PP; Kassubek J; Jost WH
    J Neural Transm (Vienna); 2023 Jun; 130(6):847-861. PubMed ID: 36964457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness Analysis of COMT-inhibitors as Adjuvant Treatments to Levodopa in Patients with Advanced Parkinson's Disease.
    Kwak N; Lee MJ; Kang HY; Lee H
    Clin Ther; 2024 Sep; 46(9):670-676. PubMed ID: 39089982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opicapone to Treat Early Wearing-off in Parkinson's Disease Patients: The Korean ADOPTION Trial.
    Lee JY; Ma HI; Ferreira JJ; Rocha JF; Sung YH; Song IU; Ahn TB; Kwon DY; Cheon SM; Kim JM; Lee CS; Lee PH; Park JH; Lee JH; Park MY; Kim SJ; Baik JS; Choi SM; Shin HW; Lee HW; Kang SY; Jeon B
    Mov Disord Clin Pract; 2024 Jun; 11(6):655-665. PubMed ID: 38594812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
    Reichmann H; Lees A; Rocha JF; Magalhães D; Soares-da-Silva P;
    Transl Neurodegener; 2020 Mar; 9(1):9. PubMed ID: 32345378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Relevance of COMT inhibitors in the treatment of motor fluctuations].
    Jost WH; Buhmann C; Classen J; Eggert K; Kohl Z; Outeiro T; Tönges L; Woitalla D; Reichmann H
    Nervenarzt; 2022 Oct; 93(10):1035-1045. PubMed ID: 35044481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opicapone for the treatment of Parkinson's disease: an update.
    Salamon A; Zádori D; Szpisjak L; Klivényi P; Vécsei L
    Expert Opin Pharmacother; 2019 Dec; 20(18):2201-2207. PubMed ID: 31670988
    [No Abstract]   [Full Text] [Related]  

  • 27. Opicapone for Parkinson's disease: clinical evidence and future perspectives.
    Leung C; Rascol O; Fabbri M
    Neurodegener Dis Manag; 2021 Jun; 11(3):193-206. PubMed ID: 33745288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Opicapone for the treatment of Parkinson's disease: real-life data in Spain].
    López-Ariztegui N; Mata-Alvarez Santullano M; Tegel I; Almeida F; Sarasa P; Rojo R; Rico-Villademoros F; Abril-Jaramillo J; Bermejo P; Borrue C; Caballol N; Campins-Romeu M; Clavero P; García-Caldentey J; Gómez-Mayordomo V; Labandeira C; Martí-Andrés G; Martínez-Castrillo JC; Martinez-Poles J; Muñoz T; Salom JM; Valderrama-Martín C; Vinagre-Aragón A
    Rev Neurol; 2021 Dec; 73(s02):S01-S14. PubMed ID: 34897643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease.
    Rocha JF; Ferreira JJ; Falcão A; Santos A; Pinto R; Nunes T; Almeida L; Soares-da-Silva P
    Clin Pharmacol Drug Dev; 2016 May; 5(3):232-40. PubMed ID: 27163503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opicapone: Once-Daily COMT Inhibitor for the Treatment of Wearing Off in Parkinson's Disease.
    Craft BM; Baker DE; Levien TL
    Sr Care Pharm; 2022 Feb; 37(2):55-61. PubMed ID: 35082010
    [No Abstract]   [Full Text] [Related]  

  • 31. COMT Inhibitors in the Management of Parkinson's Disease.
    Fabbri M; Ferreira JJ; Rascol O
    CNS Drugs; 2022 Mar; 36(3):261-282. PubMed ID: 35217995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Lees AJ; Ferreira J; Rascol O; Poewe W; Rocha JF; McCrory M; Soares-da-Silva P;
    JAMA Neurol; 2017 Feb; 74(2):197-206. PubMed ID: 28027332
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.
    Lees AJ; Ferreira J; Rascol O; Reichmann H; Stocchi F; Tolosa E; Poewe W
    Expert Rev Neurother; 2017 Jul; 17(7):649-659. PubMed ID: 28580819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opicapone for the treatment of Parkinson's disease.
    Rodrigues FB; Ferreira JJ
    Expert Opin Pharmacother; 2017 Mar; 18(4):445-453. PubMed ID: 28234566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease.
    Kaakkola S
    Drugs; 2000 Jun; 59(6):1233-50. PubMed ID: 10882160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.
    Bonifácio MJ; Sutcliffe JS; Torrão L; Wright LC; Soares-da-Silva P
    Neuropharmacology; 2014 Feb; 77():334-41. PubMed ID: 24148813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.
    Bonifácio MJ; Torrão L; Loureiro AI; Palma PN; Wright LC; Soares-da-Silva P
    Br J Pharmacol; 2015 Apr; 172(7):1739-52. PubMed ID: 25409768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opicapone: A Review in Parkinson's Disease.
    Scott LJ
    CNS Drugs; 2021 Jan; 35(1):121-131. PubMed ID: 33428178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Catechol-O-methyltransferase inhibitors versus active comparators for levodopa-induced complications in Parkinson's disease.
    Deane KH; Spieker S; Clarke CE
    Cochrane Database Syst Rev; 2004 Oct; 2004(4):CD004553. PubMed ID: 15495118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.